BJU International最新文献

{"title":"Cancer detection in the European Randomised Study of Screening for Prostate Cancer (ERSPC)","authors":"Niko Pasanen,&nbsp;Kirsi Talala,&nbsp;Sebastiaan Remmers,&nbsp;Teuvo L. J. Tammela,&nbsp;Jonas Hugosson,&nbsp;Rebecka Arnsrud Godtman,&nbsp;Kimmo Taari,&nbsp;Chris Bangma,&nbsp;Elly Den Hond,&nbsp;Vera Nelen,&nbsp;Stephen Wyler,&nbsp;Maciej Kwiatkowski,&nbsp;Donella Puliti,&nbsp;Giuseppe Gorini,&nbsp;Luis Gonzàlez,&nbsp;Marcos Lujan,&nbsp;Monique J. Roobol,&nbsp;Anssi Auvinen","doi":"10.1111/bju.70380","DOIUrl":"10.1111/bju.70380","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To provide a comprehensive analysis regarding outcomes of repeated screening and detection of low-grade versus high-grade cancer from the European Randomised Study of Screening for Prostate Cancer (ERSPC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>This study analysed men aged 55–69 years at random across the ERSPC trial centres except France. Men in the screening arm were classified as ever-attenders (who attended at least one screening cycle) or non-attenders (who did not attend a specific screening cycle). Cancer detection rates (CDRs) were calculated by age group and centre across three screening cycles. A secondary analysis incorporated interval prostate cancer (PCa) cases—those diagnosed outside the screening protocol—among both ever-attenders and non-attenders. Incidence data from the control arm were included for comparison.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Based on screen-detected cases, CDRs were consistently higher for low-grade than for intermediate- and high-grade cases across all centres and screening cycles. Trends in CDRs for high-grade cases varied by centre: CDRs decreased from the first to the second cycle and increased again during the third cycle in most centres, whereas CDRs increased in Spain with each successive screening cycle.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The ERSPC data show a decreasing detection rate for low-grade cancer and substantial variation in the detection rate for intermediate- and high-grade cancer between centres across repeated screening rounds. Increasing interval and non-attender cancers indicate diminishing effectiveness of uniform screening schedules. These findings support personalised screening approaches and improved strategies to maintain participation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"138 5","pages":"822-830"},"PeriodicalIF":4.1,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bju.70380","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148379730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health-related quality of life and patient-reported outcome measures in economic evaluation of urological technologies: challenges and opportunities","authors":"Mohammed El Bahnasawi,&nbsp;Charlotte Moss,&nbsp;Netty Kinsella,&nbsp;Kathie Alexina Wong,&nbsp;Mieke Van Hemelrijck","doi":"10.1111/bju.70365","DOIUrl":"10.1111/bju.70365","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To examine the role of health-related quality of life (HRQoL) assessments and patient-reported outcome measures (PROMs) in the economic evaluation of urological interventions, highlighting methodological challenges, and identifying areas for future development.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This narrative review synthesises key frameworks for economic evaluation in urology, describes methods for utility derivation, and critically appraises the application of both generic and disease-specific PROMs. Evidence is drawn from major urological trials and model-based evaluations, with attention to their impact on health technology assessment decisions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Patient-reported outcome measures underpin cost-utility analyses across the full spectrum of urological conditions, including benign prostatic hyperplasia (BPH), urinary incontinence, overactive bladder, bladder cancer, renal cancer, and prostate cancer. Generic instruments such as the EuroQoL five Dimensions (EQ-5D) and 36-item Short-Form Health Survey (SF-36) facilitate cross-disease comparison but may lack sensitivity to urological symptoms. Disease-specific tools (e.g., International Prostate Symptom Score, Overactive Bladder Questionnaire, 26-item Expanded Prostate cancer Index Composite) provide granularity but often require mapping to utility values, introducing uncertainty. Trial-based evaluations (e.g., Trans European Research into the use of Management Policies for LUTS suggestive of BPH in Primary Healthcare [TRIUMPH], Single-Incision Mini-Slings [SIMS], Refractory Overactive Bladder: Sacral NEuromodulation vs BoTulinum Toxin Assessment [ROSETTA]) demonstrate that PROM-derived quality-adjusted life year differences can decisively influence cost-effectiveness. Surgery-related PROMs including the Consultation and Relational Empathy measure can capture important short-term recovery outcomes not measured by generic tools.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Health-related quality of life and PROMs are foundational to value-based urological care. Accurate and context-sensitive measurement ensures that cost-utility analyses reflect patient experience as well as clinical outcomes. Future priorities include development of preference-based urology-specific PROMs, improved digital/electronic PROM capture, validation of mapping algorithms, and integration of surgery-related PROMs into economic evaluations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"138 5","pages":"750-758"},"PeriodicalIF":4.1,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bju.70365","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148355681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The physiology of the upper urinary tract in endourological times – a narrative review","authors":"Emmeli Grøne Lykkegaard,&nbsp;Anne Sofie Peetz Brandt,&nbsp;Louise Faurholt Øbro,&nbsp;Helene Jung","doi":"10.1111/bju.70434","DOIUrl":"10.1111/bju.70434","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To synthesise current knowledge of upper urinary tract (UUT) physiology in the context of contemporary endourology, with particular emphasis on the interacting biological stressors associated with endourological intervention and the tissue responses they provoke.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and Methods</h3>\u0000 \u0000 <p>A narrative review of the literature was conducted using PubMed/MEDLINE. Relevant experimental, translational and clinical studies examining UUT physiology, tissue injury and biological responses to ureteroscopy, percutaneous nephrolithotomy, irrigation and intrarenal pressure, laser lithotripsy, suction-assisted technologies, intracavitary therapies and ureteral stents were considered.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The UUT is a biologically active organ whose function depends on coordinated peristalsis, urothelial barrier integrity, pressure regulation and preserved tissue perfusion. Contemporary endourological procedures expose the UUT to interacting mechanical, pressure-related, parenchymal, thermal and chemical stressors that may influence urothelial permeability, intrarenal backflow, inflammation, tissue repair and fibrosis. Tissue tolerance appears to vary considerably between individuals and may be influenced by factors including hydronephrosis, collecting-system compliance and papillary morphology. Despite these biological effects, current outcome assessment remains predominantly focused on technical success, while physiological and biological safety endpoints remain poorly defined.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Future advances in endourology should integrate physiological and biological outcome measures alongside traditional surgical metrics. Improved understanding of UUT physiology and tissue responses may help define evidence-based thresholds and support endourological treatment that is both technically effective and biologically safe.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"138 5","pages":"777-785"},"PeriodicalIF":4.1,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient selection for prostate cancer focal therapy guided by mpMRI–PSMA PET concordance and pathology review","authors":"Armando Stabile,&nbsp;Michele Brancaccio,&nbsp;Pietro Scilipoti,&nbsp;Francesco Maria Barletta,&nbsp;Simone Scuderi,&nbsp;Leonardo Quarta,&nbsp;Andrea Cosenza,&nbsp;Paolo Zaurito,&nbsp;Maria Elena Porzi,&nbsp;Giulio Imperiale,&nbsp;Giorgio Brembilla,&nbsp;Francesco De Cobelli,&nbsp;Cristiano Pini,&nbsp;Arturo Chiti,&nbsp;Maurizio Colecchia,&nbsp;Francesco Montorsi,&nbsp;Giorgio Gandaglia,&nbsp;Alberto Briganti","doi":"10.1111/bju.70420","DOIUrl":"10.1111/bju.70420","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"138 5","pages":"803-806"},"PeriodicalIF":4.1,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148709482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of triplet therapy combined with robot-assisted cytoreductive prostatectomy for high-volume metastatic prostate cancer: a multicentre randomised controlled trial protocol","authors":"Xiangwei Yang,&nbsp;Zhuobin He,&nbsp;Jian Chen,&nbsp;Hanqi Lei,&nbsp;Binyuan Yan,&nbsp;Linze Chen,&nbsp;Hong Liu,&nbsp;Jun Pang","doi":"10.1111/bju.70421","DOIUrl":"10.1111/bju.70421","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Prostate cancer (PCa) is the second most common cancer in men. For patients with high-volume metastatic PCa (mPCa) who are fit for docetaxel, a triplet therapy regimen consisting of androgen deprivation therapy (ADT), chemotherapy, and an androgen receptor pathway inhibitor (ARPI) is recommended. Adding local radiotherapy to triplet therapy has been shown to alleviate symptoms and reduce disease progression. However, the benefit of combining triplet therapy with local surgery remains unclear and warrants further investigation in the present study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Study Design</h3>\u0000 \u0000 <p>This is an open-label, prospective, two-arm, multicentre, randomised controlled trial.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Endpoints</h3>\u0000 \u0000 <p>Primary endpoints are progression-free survival (PFS) and the 1-year PFS rate. Disease progression is defined as prostate-specific antigen (PSA) progression, radiological progression, or unequivocal clinical progression. Secondary endpoints include overall survival (OS) and health-related quality of life (HRQoL).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and Methods</h3>\u0000 \u0000 <p>Patients aged 18–75 years with high-volume mPCa will receive ADT (triptorelin 15 mg every 3 months), four–six cycles of chemotherapy (docetaxel 75 mg/m² every 3 weeks), and an ARPI (rezvilutamide 240 mg once daily). Patients achieving a PSA level ≤0.2 ng/mL and deemed suitable candidates for surgery will be enrolled. A total of 88 eligible patients will be randomised in a 1:1 ratio. The control group will continue treatment with triptorelin and rezvilutamide, while the experimental group will receive robot-assisted cytoreductive prostatectomy in addition to triptorelin and rezvilutamide. Baseline PSA levels will be recorded and re-examined at each chemotherapy cycle and every 3 months thereafter. Radiological evaluations will be performed every 6 months. Clinical progression will be assessed based on pain severity, performance status, and the need to initiate new anticancer therapy. HRQoL will be evaluated every 3 months. PFS and OS will be estimated using Kaplan–Meier curves and compared with the log-rank test.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>Chinese Clinical Trial Registry: ChiCTR2600121819</p>\u0000 </section>\u0000 </div>","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"138 5","pages":"807-814"},"PeriodicalIF":4.1,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bju.70421","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148726383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bladder preservation with systemic therapy alone: are we losing sight of survival?","authors":"Alec Zhu,&nbsp;Pierre-Etienne Gabriel,&nbsp;John P. Sfakianos","doi":"10.1111/bju.70441","DOIUrl":"10.1111/bju.70441","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"138 5","pages":"798-800"},"PeriodicalIF":4.1,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148863324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-in-human outpatient management of recurrent NMIBC with the Multi4 instrument","authors":"Miden Melle-Hannah,&nbsp;Henrik Kjölhede,&nbsp;Henrik Bäckdahl,&nbsp;Martin E. Johansson,&nbsp;Joakim Håkansson","doi":"10.1111/bju.70445","DOIUrl":"10.1111/bju.70445","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate the feasibility, safety and diagnostic performance of outpatient management of recurrent non-muscle-invasive bladder cancer (NMIBC) under local anaesthesia using the Multi4 instrument, a series of preclinical studies were performed followed by a first-in-human clinical investigation. NMIBC is associated with frequent recurrence, requiring repeated transurethral resection of the bladder (TUR-B) under anaesthesia, resulting in substantial healthcare burden. The Multi4 instrument integrates local anaesthesia injection, diathermy biopsy, coagulation and automated tissue retrieval. The primary objective was to determine whether Multi4 provides histologically evaluable biopsies in an outpatient setting, and secondary objectives included safety, usability, patient-reported outcomes and health-economic impact.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Preclinical <i>in vivo</i> evaluation was performed in 13 pigs to assess safety, biopsy quality, coagulation efficacy and perforation risk. A prospective, open-label, single-arm clinical investigation enrolled 18 adults with recurrent Ta/T1 NMIBC (≤10 mm lesions). Procedures were performed under local anaesthesia using flexible cystoscopy. The primary endpoint was the proportion of evaluable biopsies. Secondary endpoints included adverse events, usability, pain (0–10 scale), EQ-5D and cost comparison versus standard TUR-B. Diagnostic yield was also assessed at the patient level.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 550 porcine biopsies demonstrated immediate haemostasis and preserved tissue architecture suitable for histological assessment. Perforation occurred after 7–11 sequential biopsies at the same location, indicating a wide safety margin. Clinically, 134/145 biopsies (92%) were evaluable and the primary endpoint was met. Diagnostic yield per patient was 89%. No device-related adverse events or Clavien–Dindo complications occurred. All procedures were completed under local anaesthesia without conversion to standard TUR-B or use of additional instruments. The median pain score was 0.5/10. Estimated per-procedure cost reduction was 73–89% versus TUR-B.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Multi4 enables feasible and safe outpatient biopsy and lesion management of small recurrent NMIBC under local anaesthesia with substantially reduced resource use while maintaining diagnostic reliability.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"138 5","pages":"867-876"},"PeriodicalIF":4.1,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bju.70445","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148922826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advances in the management of prostate cancer","authors":"","doi":"10.1111/bju.70476","DOIUrl":"10.1111/bju.70476","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"138 5","pages":"745-746"},"PeriodicalIF":4.1,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149151787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gynaecomastia secondary to transdermal oestradiol used for androgen deprivation therapy: informed reality vs subjective fear","authors":"Carly Sears,&nbsp;Robert Watson,&nbsp;Eric Brown,&nbsp;Badra Abbas,&nbsp;Paul Schellhammer,&nbsp;Richard Wassersug","doi":"10.1111/bju.70374","DOIUrl":"10.1111/bju.70374","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To provide information that can aid patients with prostate cancer (PCa) and their uro-oncologists in shared decision-making discussions about androgen deprivation therapy (ADT), with transdermal oestradiol (tE2) as one option. We do so by summarising recent literature on breast growth in genetic males undergoing treatment with exogenous E2. Based on the amount of breast development observed in this population, we estimate the maximum amount of breast growth that patients with PCa can expect, if they elect tE2 for ADT. We also present data on risks and management of mastalgia associated with tE2.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We summarise findings from five studies involving a total of 480 trans women (i.e., genetic males) undergoing gender-affirming hormone treatment with exogenous oestrogen.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Exogenous E2 typically induces less than an A-cup size among trans women. The majority of breast growth occurs within the first year of treatment. We present this evidence to illustrate that the degree of gynaecomastia patients with PCa can expect if they elect tE2 for ADT is quite modest. This information can allay the often-heightened concern patients with PCa and their uro-oncologists may have regarding gynaecomastia induced by tE2 when used for ADT.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Development of breast tissue in genetic males taking exogenous E2 tends to be mild and typically results in less than A-cup size. Mastalgia in the form of breast and nipple sensitivity is common with E2 treatment in patients with PCa but is transient in most cases, responds to topical anti-inflammatory agents, and can be managed with neurectomy in severe cases. This information can help clinicians provide accurate counselling and mitigate misconceptions that may dissuade patients from considering tE2 for their ADT.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"138 5","pages":"815-821"},"PeriodicalIF":4.1,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148432074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of discordance between preoperative MRI and intraoperative ultrasound on surgical strategy in renal cell carcinoma with venous tumour thrombus","authors":"Baris Esen,&nbsp;Reza Lahiji,&nbsp;Dattatraya Patil,&nbsp;William Luke,&nbsp;Viraj A. Master","doi":"10.1111/bju.70418","DOIUrl":"10.1111/bju.70418","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"138 5","pages":"801-803"},"PeriodicalIF":4.1,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148687927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}